1. Volume Effect and Retention
The uniform sized hyaluronic acid particles with optimal
viscoelasticity can maintain a long-lasting volume.
2. Safe to Use on Patients
MONALISA is safe to use on patients due to low level
of endotoxin and essentially no BDDE residue.
3. Easy Procedural Operation
The ergonomically-designed rod and grip allow the even distribution of pressure during injection to enable an accurate and safe treatment for both the clinician and the patient.
4. Highly Pure Hyaluronic Acid
GENOSS implements a strict quality control system through direct involvement
in the entire production process from the base material of hyaluronic acid to the final product.
5. Global Standard Quality Control
To guarantee the quality of MONALISA, GENOSS strictly fulfills and complies
with the international quality regulations, including KGMP, ISO 13485 and ISO 9001.
Thin-wall needle

Thin-wall needle enables smooth injection which reduces patient’s discomfort during the procedure

MONALISA Lidocaine

30G TW needle for Soft and Mild type
27G TW needle for Hard and Ultra type

MONALISA

27G TW needle for Soft, Mild and Hard type

Ergonomic Design

Ergonomically-designed grips enable an accurate, convenient and safe treatment.

Design
Grip
Safe to Use on Patients

The risk of allergic reaction, edema and other adverse side effects were minimized by significantly reducing
the BDDE (chemical agent used to cross-link hyaluronic acid) to the point where it is undetectable.

MONALISA Performance Test
Genoss Research Institute
Standard Result
Appearance No impurities, transparent and colorless gel Pass
Content 18 ~ 22mg 20.1mg
pH 6.5 ~7.5 7.18
BDDE Residues < 2ppm Not Detected
Heavy Metal < 10ppm Pass
Volume > 1.0mL Pass
MONALISA Lidocaine Performance Test
Genoss Research Institute
Standard Result
Appearance No impurities, transparent and colorless gel Pass
Content 18 ~ 22mg 20.1mg
pH 6.5 ~7.5 7.18
BDDE Residues < 2ppm Not Detected
Heavy Metal < 10ppm Pass
Volume > 1.0mL Pass

* What is BDDE?

1,4-butanediol diglycidyl ether (BDDE) is a chemical cross-linking agent that produces hyaluronic acid into a gel form.
The BDDE residue should not exceed 2ppm. In the MONALISA, the BDDE residue was undetectable.
Volume Maintenance

Hy-BRID technology enables the production of highly dense and uniform particles in MONALISA.
The volume is maintained for at least 6 months before the dissolution process begins.

Uniform particle size and dissolution rate

Injection of the MONALISA into the treatment site

MONALISA has uniform particle size which yields a volume of natural feel.

MONALISA maintains the same dissolution rate and it is gradually and naturally dissolved and discharged from the body.

Viscoelasticity with the Optimal Ratio

The application of the Hy-BRID technology allows the MONALISA to achieve the ideal
viscoelasticity for greater volume and durability compared to current competitors.